Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells

Jiang, Donghai; Sui, Meihua; Zhong, Wansi; Huang, Yuan; Fan, Weimin

doi:10.1016/j.canlet.2013.02.059

Cited by 34 publications

(46 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,33). Human triplenegative breast cancer (TNBC; MDA-MB-231), prostate cancer (DU145), and colorectal carcinoma (LoVo) cell lines were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China) between 2012 and 2017 and were authenticated using short tandem repeat DNA fingerprinting.…”

Section: Cell Lines and Cell Culturementioning

confidence: 99%

New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

et al. 2017

Self Cite

View full text Add to dashboard Cite

The therapeutic index for chemotherapeutic drugs is determined in part by systemic toxicity, so strategies for dose intensification to improve efficacy must also address tolerability. In addressing this issue, we have investigated a novel combinatorial strategy of reconstructing a drug molecule and using sequential drug-induced nanoassembly to fabricate supramolecular nanomedicines (SNM). Using cabazitaxel as a target agent, we established that individual synthetic prodrugs tethered with polyunsaturated fatty acids were capable of recapitulating self-assembly behavior independent of exogenous excipients. The resulting SNM could be further refined by PEGylation with amphiphilic copolymers suitable for preclinical studies. Among these cabazitaxel derivatives, docosahexaenoic acid-derived compound 1 retained high antiproliferative activity. SNM assembled with compound 1 displayed an unexpected enhancement of tolerability in animals along with effective therapeutic efficacy in a mouse xenograft model of human cancer, compared with free drug administered in its clinical formulation. Overall, our studies showed how attaching flexible lipid chains to a hydrophobic and highly toxic anticancer drug can convert it to a systemic self-deliverable nanotherapy, preserving its pharmacologic efficacy while improving its safety profile. Cancer Res; 77(24); 6963-74. Ó2017 AACR.

show abstract

Section: Cell Lines and Cell Culturementioning

confidence: 99%

New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…It was also reported that drug-resistant cell line developed by time-stepwise increments administration exhibited enhanced migration (17). These contradictions may be due to the different drugs and parental cells used in the establishment, which suggested that different administration strategies with a single drug could induce distinct phenotypes of drug-resistant cell lines.…”

Section: Discussionmentioning

confidence: 97%

“…Twentyman et al (20) adopted a pulsatile approach and found that the cell line was unstable during the first 3 weeks of drug-free growth, but with no loss of resistance if maintained in drug-containing media. However jiang et al (17) reported that a cell line displayed stable resistant property using the pulsatile approach.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies

Jiang

Shen

et al. 2016

Oncology Reports

Self Cite

View full text Add to dashboard Cite

Resistance to chemotherapy is a major obstacle to the successful treatment of breast cancer patients. Recently, we successfully established two vinorelbine-resistant sublines, BC-DS and BC-TS, from the human breast cancer cell line BCap37, with different 'two-stage screening methods'. Interestingly, though BC-DS and BC-TS were developed from the same BCap37 cell line with the same drug, they showed remarkable differences. Compared with the parental BCap37 cells both BC-DS and BC-TS had resistance to vinorelbine, but the resistant characterizations are both unstable. BC-DS showed increased migration capability while BC-TS showed reduced migration capability. When investigating their multidrug resistance, we found BC-DS became more sensitive to methotrexate, which suggested that combination of MTX and vinorelbine could be a new treatment strategy. Moreover, BC-DS and BC-TS overexpressed P-glycoprotein at different levels. Our research also showed that the present clinical usage of vinorelbine is reasonable. These findings suggest that the vinorelbine-induced multiple drug resistance (MDR) sublines may be used as an in vitro model not only to further elucidate possible mechanisms of MDR involved in the human breast cancer, but also to find methods to optimize the curative effect of vinorelbine in clinic.

show abstract

“…Bads-200 cells were maintained in medium containing 200 nM paclitaxel (20), and KBv200 were grown in medium added 100 nM vincristine to keep their drug resistance characteristics (25). …”

Section: Methodsmentioning

confidence: 99%

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression

et al. 2016

Self Cite

View full text Add to dashboard Cite

Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In this study, we evaluated the combination treatment of fulvestrant and doxorubicin in ER-negative multidrug-resistant (MDR) breast cancer cell lines Bads-200 and Bats-72. Fulvestrant potentiated doxorubicin-induced cytotoxicity, apoptosis and G2/M arrest with upregulation of cyclin B1. It functioned as a substrate for P-glycoprotein (P-gp) without affecting its expression. Furthermore, fulvestrant not only restored the intracellular accumulation of doxorubicin but also relocalized it to the nuclei in Bats-72 and Bads-200 cells, which may be another potential mechanism of reversal of P-gp mediated doxorubicin resistance. These results indicated that the combination of fulvestrant and doxorubicin-based chemotherapy may be feasible and effective for patients with advanced breast cancer.

show abstract

Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells

Cited by 34 publications

References 33 publications

New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Distinct characterization of two vinorelbine-resistant breast cancer cell lines developed by different strategies

Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression

Contact Info

Product

Resources

About